KRMD Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -7.48% compared to KORU Medical Systems, Inc.'s net margin of -13.47%. KORU Medical Systems, Inc.'s return on equity of -22.13% beat Accuray, Inc.'s return on equity of -60.6%.

KORU Medical Systems, Inc. has a consensus price target of $6.60, signalling upside risk potential of 44.74%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 392.88%. Given that Accuray, Inc. has higher upside potential than KORU Medical Systems, Inc., analysts believe Accuray, Inc. is more attractive than KORU Medical Systems, Inc..

KORU Medical Systems, Inc. has a beta of 0.439, which suggesting that the stock is 56.111% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.151, suggesting its more volatile than the S&P 500 by 15.124%.

KORU Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KORU Medical Systems, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

KORU Medical Systems, Inc. quarterly revenues are $10.4M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. KORU Medical Systems, Inc.'s net income of -$778K is higher than Accuray, Inc.'s net income of -$13.8M. Notably, KORU Medical Systems, Inc.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KORU Medical Systems, Inc. is 5.38x versus 0.13x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -7.48% compared to KORU Medical Systems, Inc.'s net margin of -14.54%. KORU Medical Systems, Inc.'s return on equity of -22.13% beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.

KORU Medical Systems, Inc. has a consensus price target of $6.60, signalling upside risk potential of 44.74%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 82.74%. Given that Alphatec Holdings, Inc. has higher upside potential than KORU Medical Systems, Inc., analysts believe Alphatec Holdings, Inc. is more attractive than KORU Medical Systems, Inc..

KORU Medical Systems, Inc. has a beta of 0.439, which suggesting that the stock is 56.111% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.

KORU Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KORU Medical Systems, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

KORU Medical Systems, Inc. quarterly revenues are $10.4M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. KORU Medical Systems, Inc.'s net income of -$778K is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, KORU Medical Systems, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KORU Medical Systems, Inc. is 5.38x versus 2.74x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -7.48% compared to KORU Medical Systems, Inc.'s net margin of 12.68%. KORU Medical Systems, Inc.'s return on equity of -22.13% beat Boston Scientific Corp.'s return on equity of 12.46%.

KORU Medical Systems, Inc. has a consensus price target of $6.60, signalling upside risk potential of 44.74%. On the other hand Boston Scientific Corp. has an analysts' consensus of $106.78 which suggests that it could grow by 45.34%. Given that Boston Scientific Corp. has higher upside potential than KORU Medical Systems, Inc., analysts believe Boston Scientific Corp. is more attractive than KORU Medical Systems, Inc..

KORU Medical Systems, Inc. has a beta of 0.439, which suggesting that the stock is 56.111% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

KORU Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KORU Medical Systems, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

KORU Medical Systems, Inc. quarterly revenues are $10.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. KORU Medical Systems, Inc.'s net income of -$778K is lower than Boston Scientific Corp.'s net income of $670M. Notably, KORU Medical Systems, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 37.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KORU Medical Systems, Inc. is 5.38x versus 5.47x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -7.48% compared to KORU Medical Systems, Inc.'s net margin of -316.61%. KORU Medical Systems, Inc.'s return on equity of -22.13% beat Plus Therapeutics, Inc.'s return on equity of --.

KORU Medical Systems, Inc. has a consensus price target of $6.60, signalling upside risk potential of 44.74%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1928.02%. Given that Plus Therapeutics, Inc. has higher upside potential than KORU Medical Systems, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than KORU Medical Systems, Inc..

KORU Medical Systems, Inc. has a beta of 0.439, which suggesting that the stock is 56.111% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

KORU Medical Systems, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KORU Medical Systems, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

KORU Medical Systems, Inc. quarterly revenues are $10.4M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. KORU Medical Systems, Inc.'s net income of -$778K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, KORU Medical Systems, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KORU Medical Systems, Inc. is 5.38x versus 4.35x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.